Steven Robert Pacelli net worth and biography

Steven Pacelli Biography and Net Worth

Insider of DexCom

Steve Pacelli is Executive Vice President and Managing Director, Dexcom Ventures.

In this role, Steve is focused on investment opportunities in sensing technology, data analytics, remote patient monitoring and population health, broadening Dexcom’s commitment to advancing better outcomes in healthcare.

Prior to this role, Steve was Executive Vice President of Strategy and Corporate Development from 2012 to 2021. Since joining Dexcom in April 2006, Steve has served in roles of increasing responsibility, including Chief Operating Officer, Chief Administrative Officer, Senior Vice President of Corporate Affairs and Vice President of Legal Affairs.

Prior to Dexcom, Steve served as a corporate attorney specializing in finance, mergers and acquisitions, and general corporate matters, and in an executive role as general counsel of several privately held companies.

Steve currently serves as a member of the Board of Directors of Biocom California, the largest and most experienced leader and advocate for California’s life science sector. He also serves as a member of the Board of Directors of Connect, a community nonprofit supporting innovators and entrepreneurs in Southern California by providing access to investors, mentors, and education, and as a member of the Board of Directors of EvoNexus, California’s leading non-profit startup technology incubator.

Steve is also a dedicated philanthropist, choosing to focus his efforts as a member of the Board of Directors of Big Brothers Big Sisters of San Diego, an organization dedicated to creating and supporting one-to-one mentoring relationships that ignite the power and promise of youth. He also serves as a member of the Board of Trustees of Pacific Ridge School, a group of dedicated and informed community leaders who are passionate about the value of education and are committed to building and strengthening the school.

Steve earned a Bachelor of Arts from the University of California, Los Angeles, and a JD from the University of Virginia. He is a member of the State Bar of California.

What is Steven Robert Pacelli's net worth?

The estimated net worth of Steven Robert Pacelli is at least $11.49 million as of August 23rd, 2022. Mr. Pacelli owns 137,700 shares of DexCom stock worth more than $11,485,557 as of October 3rd. This net worth evaluation does not reflect any other investments that Mr. Pacelli may own. Learn More about Steven Robert Pacelli's net worth.

How do I contact Steven Robert Pacelli?

The corporate mailing address for Mr. Pacelli and other DexCom executives is 6340 SEQUENCE DRIVE, SAN DIEGO CA, 92121. DexCom can also be reached via phone at (858) 200-0200 and via email at [email protected] Learn More on Steven Robert Pacelli's contact information.

Has Steven Robert Pacelli been buying or selling shares of DexCom?

Steven Robert Pacelli has not been actively trading shares of DexCom during the last ninety days. Most recently, Steven Robert Pacelli sold 1,000 shares of the business's stock in a transaction on Tuesday, August 23rd. The shares were sold at an average price of $84.21, for a transaction totalling $84,210.00. Following the completion of the sale, the director now directly owns 137,700 shares of the company's stock, valued at $11,595,717. Learn More on Steven Robert Pacelli's trading history.

Who are DexCom's active insiders?

DexCom's insider roster includes Donald Abbey (EVP), Steven Altman (Director), Nicholas Augustinos (Director), Andrew Balo (Insider), Quentin Blackford (COO), Richard Collins (Director), Richard Doubleday (EVP), Paul Flynn (EVP), Mark Foletta (Director), Bridgette Heller (Director), Barbara Kahn (Director), Jacob Leach (EVP), Jeffrey Moy (EVP), Patrick Murphy (EVP), Steven Pacelli (Insider), Chad Patterson (EVP), Barry Regan (EVP), Kevin Sayer (CEO), Shelly Selvaraj (SVP), Sumi Shrishrimal (SVP), Jay Skyler (Director), Sadie Stern (EVP), and Jereme Sylvain (CAO). Learn More on DexCom's active insiders.

Are insiders buying or selling shares of DexCom?

During the last twelve months, insiders at the medical device company sold shares 30 times. They sold a total of 59,010 shares worth more than $27,546,536.39. The most recent insider tranaction occured on August, 23rd when Director Steven Robert Pacelli sold 1,000 shares worth more than $84,210.00. Insiders at DexCom own 0.4 % of the company. Learn More about insider trades at DexCom.

Information on this page was last updated on 8/23/2022.

Steven Robert Pacelli Insider Trading History at DexCom

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
8/23/2022Sell1,000$84.21$84,210.00137,700View SEC Filing Icon  
7/25/2022Sell1,000$83.07$83,070.00138,700View SEC Filing Icon  
6/23/2022Sell1,000$72.55$72,550.00139,700View SEC Filing Icon  
5/24/2022Sell250$296.33$74,082.5035,175View SEC Filing Icon  
4/25/2022Sell250$439.94$109,985.0035,425View SEC Filing Icon  
3/23/2022Sell250$459.98$114,995.00View SEC Filing Icon  
2/23/2022Sell250$394.33$98,582.50View SEC Filing Icon  
1/24/2022Sell250$416.77$104,192.50View SEC Filing Icon  
12/23/2021Sell250$573.91$143,477.50View SEC Filing Icon  
11/23/2021Sell250$612.26$153,065.00View SEC Filing Icon  
10/22/2021Sell250$570.00$142,500.00View SEC Filing Icon  
9/23/2021Sell6,743$573.34$3,866,031.62View SEC Filing Icon  
8/23/2021Sell1,078$516.40$556,679.20View SEC Filing Icon  
7/23/2021Sell1,079$452.18$487,902.22View SEC Filing Icon  
6/23/2021Sell1,079$426.92$460,646.68View SEC Filing Icon  
4/23/2021Sell1,079$410.31$442,724.49View SEC Filing Icon  
3/23/2021Sell1,079$360.49$388,968.71View SEC Filing Icon  
3/10/2021Sell5,566$362.92$2,020,012.72View SEC Filing Icon  
2/23/2021Sell1,079$406.98$439,131.4221,524View SEC Filing Icon  
1/22/2021Sell1,079$368.82$397,956.7821,524View SEC Filing Icon  
12/23/2020Sell1,079$359.85$388,278.1533,499View SEC Filing Icon  
11/23/2020Sell1,079$318.99$344,190.2133,499View SEC Filing Icon  
10/23/2020Sell1,079$403.18$435,031.22View SEC Filing Icon  
10/1/2020Sell2,200$411.20$904,640.00View SEC Filing Icon  
9/25/2020Sell2,000$400.07$800,140.00View SEC Filing Icon  
9/23/2020Sell1,079$395.11$426,323.6946,812View SEC Filing Icon  
9/9/2020Sell4,580$398.30$1,824,214.00View SEC Filing Icon  
8/24/2020Sell1,531$427.24$654,104.44View SEC Filing Icon  
7/23/2020Sell1,531$427.31$654,211.6151,482View SEC Filing Icon  
6/23/2020Sell1,531$409.37$626,745.4751,482View SEC Filing Icon  
5/22/2020Sell1,531$396.74$607,408.9451,482View SEC Filing Icon  
3/23/2020Sell1,531$209.23$320,331.13View SEC Filing Icon  
12/23/2019Sell1,532$213.17$326,576.4448,444View SEC Filing Icon  
9/23/2019Sell1,532$155.47$238,180.0466,821View SEC Filing Icon  
6/24/2019Sell3,116$149.65$466,309.40View SEC Filing Icon  
5/23/2019Sell3,597$116.71$419,805.8772,570View SEC Filing Icon  
4/23/2019Sell3,596$116.61$419,329.56View SEC Filing Icon  
3/22/2019Sell3,596$140.04$503,583.84View SEC Filing Icon  
2/22/2019Sell1,667$144.67$241,164.89View SEC Filing Icon  
1/23/2019Sell3,114$149.74$466,290.36View SEC Filing Icon  
12/21/2018Sell3,114$109.41$340,702.74View SEC Filing Icon  
10/23/2018Sell3,114$128.85$401,238.90View SEC Filing Icon  
9/24/2018Sell3,114$141.25$439,852.50View SEC Filing Icon  
8/23/2018Sell3,114$139.96$435,835.44View SEC Filing Icon  
7/25/2018Sell3,114$101.91$317,347.74View SEC Filing Icon  
9/25/2017Sell1,450$69.81$101,224.50View SEC Filing Icon  
7/24/2017Sell1,450$69.47$100,731.50View SEC Filing Icon  
6/23/2017Sell1,450$78.19$113,375.50View SEC Filing Icon  
10/24/2016Sell10,300$81.95$844,085.00View SEC Filing Icon  
8/23/2016Sell10,300$90.74$934,622.00View SEC Filing Icon  
6/23/2016Sell10,300$77.40$797,220.00View SEC Filing Icon  
6/8/2016Sell18,239$70.88$1,292,780.32182,518View SEC Filing Icon  
4/27/2016Sell2,361$70.39$166,190.79201,757View SEC Filing Icon  
4/4/2016Sell20,600$70.62$1,454,772.00204,118View SEC Filing Icon  
1/25/2016Sell10,300$73.24$754,372.00205,914View SEC Filing Icon  
9/23/2015Sell14,000$98.08$1,373,120.00216,214View SEC Filing Icon  
8/28/2015Sell19,854$94.67$1,879,578.18228,792View SEC Filing Icon  
8/24/2015Sell14,000$84.18$1,178,520.00248,646View SEC Filing Icon  
6/23/2015Sell14,000$77.53$1,085,420.00View SEC Filing Icon  
4/23/2015Sell39,709$69.63$2,764,937.67View SEC Filing Icon  
3/23/2015Sell14,000$61.33$858,620.00View SEC Filing Icon  
1/26/2015Sell24,532$59.67$1,463,824.44View SEC Filing Icon  
1/13/2015Sell9,468$62.22$589,098.96View SEC Filing Icon  
1/12/2015Sell20,000$59.18$1,183,600.00View SEC Filing Icon  
12/23/2014Sell14,000$54.62$764,680.00View SEC Filing Icon  
10/23/2014Sell14,000$43.60$610,400.00View SEC Filing Icon  
9/23/2014Sell14,000$40.32$564,480.00View SEC Filing Icon  
8/26/2014Sell30,000$44.56$1,336,800.00View SEC Filing Icon  
8/25/2014Sell14,000$44.24$619,360.00View SEC Filing Icon  
7/23/2014Sell14,000$38.28$535,920.00View SEC Filing Icon  
6/23/2014Sell14,000$41.02$574,280.00View SEC Filing Icon  
4/23/2014Sell14,000$35.90$502,600.00241,399View SEC Filing Icon  
3/24/2014Sell14,000$42.92$600,880.00241,399View SEC Filing Icon  
2/25/2014Sell33,368$44.93$1,499,224.24195,865View SEC Filing Icon  
1/23/2014Sell14,000$36.49$510,860.00195,865View SEC Filing Icon  
6/11/2013Sell5,000$22.31$111,550.00View SEC Filing Icon  
See Full Table

Steven Robert Pacelli Buying and Selling Activity at DexCom

This chart shows Steven Robert Pacelli's buying and selling at DexCom by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

DexCom Company Overview

DexCom logo
DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include DexCom G6, an integrated CGM system for diabetes management; Dexcom Real-Time API, which enables invited third-party developers to integrate real-time CGM data into their digital health applications and devices; Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions; and Dexcom Share, a remote monitoring system. The company's products candidature comprises Dexcom G7, a next generation G7 CGM system. DexCom, Inc. has a collaboration and license agreement with Verily Life Sciences LLC and Verily Ireland Limited to develop blood-based or interstitial glucose monitoring products. The company markets its products directly to endocrinologists, physicians, and diabetes educators. DexCom, Inc. was incorporated in 1999 and is headquartered in San Diego, California.
Read More

Today's Range

Now: $84.98
Low: $81.06
High: $85.54

50 Day Range

MA: $86.18
Low: $79.64
High: $94.18

2 Week Range

Now: $84.98
Low: $66.89
High: $164.86

Volume

2,588,967 shs

Average Volume

3,239,197 shs

Market Capitalization

$33.36 billion

P/E Ratio

177.05

Dividend Yield

N/A

Beta

1.03